These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38637505)

  • 21. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
    Russo E; Citraro R; Mula M
    Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
    Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
    Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.
    Steinhoff BJ; Staack AM
    Ther Adv Neurol Disord; 2019; 12():1756286419873518. PubMed ID: 31523280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
    Lee J; Daniels V; Sands ZA; Lebon F; Shi J; Biggin PC
    PLoS One; 2015; 10(2):e0116589. PubMed ID: 25692762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor.
    Rummel A; Häfner K; Mahrhold S; Darashchonak N; Holt M; Jahn R; Beermann S; Karnath T; Bigalke H; Binz T
    J Neurochem; 2009 Sep; 110(6):1942-54. PubMed ID: 19650874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
    Feyissa AM
    Neuropsychiatr Dis Treat; 2019; 15():2587-2600. PubMed ID: 31571877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levetiracetam inhibits THP-1 monocyte chemotaxis and adhesion via the synaptic vesicle 2A.
    Zhang Y; Hu M; Tang YY; Zhang B; Han YY; Huang ZY; Chen C; Li G
    Biochem Biophys Res Commun; 2020 Feb; ():. PubMed ID: 32067739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
    Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visualization of SV2A conformations in situ by the use of Protein Tomography.
    Lynch BA; Matagne A; Brännström A; von Euler A; Jansson M; Hauzenberger E; Söderhäll JA
    Biochem Biophys Res Commun; 2008 Oct; 375(4):491-5. PubMed ID: 18692481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding.
    Gustafsson R; Zhang S; Masuyer G; Dong M; Stenmark P
    Toxins (Basel); 2018 Apr; 10(4):. PubMed ID: 29649119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.